drugset
drugset / Trial / NCT01493596

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596 ↗

Phase 1 Completed 55 enrolled Catalyst Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindBasic science

Summary

Primary Objective: • To evaluate the safety and tolerability of ascending single oral doses of CPP-115 Secondary Objective: • To determine the pharmacokinetic profiles of CPP-115 following administration of a ascending single oral doses

Timeline

Start
2011-12
Primary completion
2012-06
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CPP-115 Small molecule — Oral

Indications

cocaine dependence